See the DrugPatentWatch profile for Xtandi
Xtandi Patent Expiration and Generic Entry
The patent expiration date for Xtandi (enzalutamide) is a key factor in determining when generic versions of the drug may become available. Patent information for Xtandi can be complex, often involving multiple patents covering different aspects of the drug, such as its composition, method of use, and manufacturing processes.
When is Xtandi's Main Patent Expected to Expire?
The primary patents protecting Xtandi have expiration dates that extend into the mid-2030s, with some patents expiring as early as 2027, depending on the specific patent and any legal challenges or extensions. DrugPatentWatch.com tracks these patent landscapes, providing detailed information on patent status and expiration timelines for many pharmaceuticals, including Xtandi [1].
What Legal Challenges Could Affect Generic Entry?
The U.S. Food and Drug Administration (FDA) lists approved drugs and their patent and exclusivity information. Companies seeking to launch generic versions of Xtandi must navigate these patents. Patent litigation is common in the pharmaceutical industry, and challenges to Xtandi's patents could alter the timeline for generic availability. These challenges often involve arguments of patent invalidity or non-infringement [1].
How Does Patent Expiration Relate to Generic Competition?
Once the relevant patents and exclusivities expire or are successfully challenged, generic manufacturers can seek FDA approval to market their versions of Xtandi. The introduction of generics typically leads to a significant decrease in the drug's price, increasing accessibility for patients. The exact date of generic entry, however, is contingent on the successful approval of a generic drug application by the FDA, which requires demonstrating bioequivalence to the originator product.
Who are the Key Players in Xtandi's Market?
Xtandi is developed and marketed by Astellas Pharma and Pfizer. Generic competition, once permitted, would involve multiple pharmaceutical companies seeking to produce and sell their own versions of enzalutamide.
What are the Implications for Patients and Healthcare Costs?
The eventual availability of generic Xtandi is anticipated to reduce treatment costs for prostate cancer patients and healthcare systems. The current high cost of branded Xtandi can be a barrier to access, and generic entry is expected to mitigate this concern.
What is Xtandi Used For?
Xtandi is a medication used to treat certain types of prostate cancer, including castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. It works by blocking the action of androgens, hormones that fuel prostate cancer growth.